期刊文献+

PBX1突变致先天性肾和尿路异常综合征伴或不伴听力损失、耳朵异常或发育迟缓1例基因型及表型分析 被引量:2

Genotype and phenotype analysis of a case of congenital anomalies of kidney and urinary tract syndrome with or without hearing loss,abnormal ears or developmental delay caused by PBX1 mutation
下载PDF
导出
摘要 先天性肾和尿路异常综合征(congenital anomalies of kidney and urinary tract syndrome,CAKUT)是以泌尿系统先天性形态缺陷为核心表型的疾病,其表型异质性强,在普通人群中表现为亚临床表现到严重危及生命的泌尿系统畸形[1-2],包括各种肾脏异常,如肾发育异常、多囊肾和肾积水等;泌尿道异常包括肾盂输尿管连接部梗阻、双输尿管、巨型输尿管、膀胱输尿管反流、尿道裂等[3-5],目前已知的与人类CAKUT相关的致病基因约50个,遗传方式以常染色体显性遗传最为常见,其中HNF1β、PAX2、DSTYK基因是散发型CAKUT中常见的致病基因[6]。除单基因变异外,拷贝数变异也可致病,其中17q12微缺失综合征和22q11.2微缺失综合征是CAKUT病例中常见的拷贝数变异[7]。先天性肾和尿路异常综合征伴或不伴听力损失、耳朵异常或发育迟缓(congenital anomalies of kidney and urinary tract syndrome with or without hearing loss,abnormal ears or developmental delay,CAKUTHED)是一种常染色体显性遗传,由PBX1基因突变致病。
作者 吴莉婷 石宇 黄道超 吴瑞 李书香 周全胜 桂俊峰 蔡奕晴 宋萃 Wu Liting;Shi Yu;Huang Daochao;Wu Rui;Li Shuxiang;Zhou Quansheng;Gui Junfeng;Cai Yiqing;Song Cui(Department of Endocrine Genetic Metabolism,National Clinical Medical Research Center for Children’s Health and Diseases,Key Laboratory of the Ministry of Education for Child Developmental Disease Research,Chongqing Key Laboratory of Pediatrics;Department of Laboratory,Chongqing Key Laboratory of Pediatrics;Pediatrics Institute,Children’s Hospital of Chongqing Medical University,Chongqing Key Laboratory of Pediatrics)
出处 《重庆医科大学学报》 CAS CSCD 北大核心 2022年第3期358-362,共5页 Journal of Chongqing Medical University
基金 国家儿童健康与疾病临床医学研究中心临床医学研究一般资助项目(编号:NCRCCHD-2020-GP-10)。
  • 相关文献

参考文献1

二级参考文献15

  • 1Sklar CA, Mertens AC, Mitby P, et al. Risk of disease re- currence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Child- hood Cancer Survivor Study [ J]. J Clin Endocrinol Metab, 2002, 87(7) :3136-3141.
  • 2Clayton PE, Cowell CT. Safety issues in children and ado- lescents during growth hormone therapy-a review [ J ]. Growth Horm IGF Res, 2000, 10(6) :306-317.
  • 3Burgert TS, Vuguin PM, DiMartino-Nardi J, et al. Assess- ing insulin resistance: application of a fasting glucose to in- sulin ratio in growth hormone-treated children [ J]. Horm Res. 2002. 57(1-2) :37-42.
  • 4Quigley CA, Gill AM, Crowe B J, et al. Safety of growth hormone treatment in pediatric patients with idiopathic short stature [J]. J Clin Endocrinol Metab, 2005, 90(9) :5188- 5196.
  • 5BIethen SL, Allen DB, Graves D, et al. Safety of recombi- nant deoxyribonucleic acid-derived growth hormone: the Na-tional Cooperative Growth Study experience [ J ]. J Clin En- docrinol Metab, 1996, 81(5) :1704-1710.
  • 6Cowell CT, Dietsch S. Adverse events during growth hor- mone therapy [J]. J Pediatr Endocrinol Metab, 1995, 8 (4) :243-252.
  • 7Cutfield WS, Wilton P, Bennmarker H, et al. Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth-hormone treatment [ J]. Lancet, 2000, 355(9204) :610-613.
  • 8Wilton P. Adverse events during GH treatment: 10 years' experience in KIGS, a pharmacoepidemiological survey [M] //Ranke MB, Wilton P, eds. Progress in growth hor- mone therapy-10 years of KIGS. Leipzig: Barth, 1999: 349 -364.
  • 9Shalet SM, Brennan BM, Reddingius RE. Growth hormone therapy and malignancy [ J]. Horm Res, 1997, 48 (Suppl 4) :29-32.
  • 10Allen DB, Rundle AC, Graves DA, et al. Risk of leukemia in children treated with human growth hormone: review and reanalysis [ J]. J Pediatr, 1997, 131( 1 Pt 2) :S32-S36.

共引文献50

同被引文献22

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部